Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 282,184 |
|
|||||
| News | - | ||||||
| Day High | 3.4872 | Low High |
|||||
| Day Low | 3.24 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rezolute Inc | RZLT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.20 | 6.17% | 3.44 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.35 | 3.24 | 3.4872 | 3.30 | 3.24 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,501 | 282,184 | $ 3.37 | $ 949,609 | - | 0.72 - 3.6276 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:41:26 | formt | 680 | $ 3.44 | USD |
Rezolute Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 130.76M | 39.63M | - | 0 | -51.79M | -1.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rezolute News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RZLT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.46 | 3.6276 | 2.4001 | 3.11 | 452,612 | 0.98 | 39.84% |
| 1 Month | 1.90 | 3.6276 | 1.85 | 2.63 | 289,170 | 1.54 | 81.05% |
| 3 Months | 1.08 | 3.6276 | 0.9199 | 1.76 | 372,555 | 2.36 | 218.52% |
| 6 Months | 1.10 | 3.6276 | 0.72 | 1.62 | 209,478 | 2.34 | 212.73% |
| 1 Year | 1.98 | 3.6276 | 0.72 | 1.62 | 123,607 | 1.46 | 73.74% |
| 3 Years | 6.54 | 17.39 | 0.72 | 3.29 | 90,861 | -3.10 | -47.40% |
| 5 Years | 20.14 | 21.20 | 0.72 | 3.39 | 80,338 | -16.70 | -82.92% |
Rezolute Description
| Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. |
